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ORIGINAL INVESTIGATION
Epicardial adipose tissue predicts incident 
cardiovascular disease and mortality in patients 
with type 2 diabetes
Regitse H. Christensen1,2* , Bernt Johan von Scholten2, Christian S. Hansen2, Magnus T. Jensen3,4, 
Tina Vilsbøll2,5, Peter Rossing2,5 and Peter G. Jørgensen4
Abstract 
Background: Cardiac fat is a cardiovascular biomarker but its importance in patients with type 2 diabetes is not clear. 
The aim was to evaluate the predictive potential of epicardial (EAT), pericardial (PAT) and total cardiac (CAT) fat in type 
2 diabetes and elucidate sex differences.
Methods: EAT and PAT were measured by echocardiography in 1030 patients with type 2 diabetes. Follow-up was 
performed through national registries. The end-point was the composite of incident cardiovascular disease (CVD) 
and all-cause mortality. Analyses were unadjusted (model 1), adjusted for age and sex (model 2), plus systolic blood 
pressure, body mass index (BMI), low-density lipoprotein (LDL), smoking, diabetes duration and glycated hemoglobin 
 (HbA1c) (model 3).
Results: Median follow-up was 4.7 years and 248 patients (191 men vs. 57 women) experienced the composite end-
point. Patients with high EAT (> median level) had increased risk of the composite end-point in model 1 [Hazard ratio 
(HR): 1.46 (1.13; 1.88), p = 0.004], model 2 [HR: 1.31 (1.01; 1.69), p = 0.038], and borderline in model 3 [HR: 1.32 (0.99; 
1.77), p = 0.058]. For men, but not women, high EAT was associated with a 41% increased risk of CVD and mortality in 
model 3 (p = 0.041). Net reclassification index improved when high EAT was added to model 3 (19.6%, p = 0.035). PAT 
or CAT were not associated with the end-point.
Conclusion: High levels of EAT were associated with the composite of incident CVD and mortality in patients with 
type 2 diabetes, particularly in men, after adjusting for CVD risk factors. EAT modestly improved risk prediction over 
CVD risk factors.
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Background
Despite aggressive treatment regimens and improved 
diagnostics, patients with type 2 diabetes remain at a 
substantially higher risk of cardiovascular complications 
compared to patients without diabetes [1]. This high-
lights the need for novel biomarkers that can improve 
early identification of patients at risk of cardiovascular 
disease (CVD). In recent years, cardiac fat [including 
epicardial (EAT) and pericardial (PAT) fat] has gained 
attention as a promising imaging biomarker of coronary 
artery disease (CAD) due to its intimate relation to the 
myocardium and coronary arteries [2]. A recent meta-
analysis of 13 studies reported that patients with type 2 
diabetes have more cardiac fat compared to individuals 
without diabetes [3]. Although, the association of EAT 
and CVD is well established in both community-based 
populations and in patients with CAD [4–11], evidence 
from patients with type 2 diabetes is still sparse [12]. 
Moreover, it remains uncertain if the association of EAT 
and CVD is truly independent from traditional risk fac-
tors in patients with type 2 diabetes. A few studies show 
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that EAT provides incremental value to existing risk fac-
tors in the prediction of future CVD in the general pop-
ulation and in patients with stable chest pain [13, 14]. 
However, the clinical relevance, as assessed by improve-
ment in risk prediction, of adding EAT, PAT and total 
cardiac fat (CAT) in the prediction of incident CVD and 
mortality has not been addressed in patients with type 
2 diabetes. Moreover, it is not known whether there are 
sex-specific differences in the pathogenicity of cardiac fat 
in type 2 diabetes.
Sex is one of the traditional risk factors of CAD. Men 
are at a higher risk compared to women of similar age 
[15] due to a different risk profile, which includes a larger 
amount of android/visceral adipose tissue in men com-
pared to a preferential gynoid fat distribution in women 
[16, 17]. The physiology of these adipose tissue depots 
differs: while gynoid adipose tissue is protective, android 
and visceral adipose tissues are proinflammatory, meta-
bolically active and prone to hypertrophy, which are 
traits believed to convey the cardiometabolic pathogenic-
ity of visceral fat [18–20]. EAT holds similar pathogenic 
characteristics with a pro-inflammatory secretory capac-
ity [21] and a high lipolytic activity which exceeds that of 
intra-abdominal fat [22]. Men are known to have more 
cardiac fat compared to women [23], yet, it is not known 
whether this translates to an increased risk of CVD.
The aim of this study was to investigate whether cardiac 
fat (CAT, EAT, PAT) could add to the prognostic value of 
traditional risk factors in the prediction of incident CVD 
and mortality in a cohort of patients with type 2 diabetes 
followed at specialized diabetes clinics. The hypothesis 
was that cardiac fat improves predictive potential of inci-
dent CVD and mortality when added to traditional CVD 
risk factors. Additionally, we tested for sex differences in 
the predictive potential of cardiac fat.
Methods
Study population
The Thousand & 2 study is a prospective cohort study 
initiated in 2011. Patients were recruited from Steno 
Diabetes Center Copenhagen and Center for Diabetes 
Research, Gentofte Hospital [24–26] and all patients with 
type 2 diabetes followed at either center were eligible to 
participate. In total, 2158 patients with type 2 diabetes 
were invited and 1030 participated. At inclusion patients 
filled out a questionnaire with information about cur-
rent medication, history of coronary heart disease (myo-
cardial infarction, percutaneous coronary intervention, 
coronary artery bypass grafting, congestive heart failure, 
and atrial fibrillation), and information about cardio-
vascular risk factors (prior stroke, peripheral artery dis-
ease, family history of CAD, and smoking status). At the 
study visit, routine blood samples using standard hospital 
assays were retrieved (cholesterol, high-density lipopro-
tein (HDL), low-density lipoprotein (LDL), triglycer-
ide, glycated hemoglobin  (HbA1c), and albuminuria) as 
described previously [24, 27]. Body mass index (BMI) 
was calculated as weight divided by the squared height.
Echocardiographic measurement of cardiac adipose tissue
EAT thickness was measured as the echo-free space 
above the free wall of the right ventricle to the epicar-
dium at end-systole in the parasternal long axis view 
perpendicular to the aortic annulus [28]. PAT thickness 
was measured as the hypoechoic space in front of EAT 
and on the external pericardium [28]. EAT and PAT were 
combined to obtain CAT. The CAT measurements have 
been previously validated in our group by assessment of 
intra- (0.93) and inter-observer (0.96) correlation coeffi-
cients [12].
Follow‑up
Follow-up was performed after 4.7 [median, interquartile 
range (IQR) 4.0; 5.3] years using ‘The Danish National 
Board of Health’s National Patient Registry and Regis-
try of Cause of Death’ as described previously [29]. The 
composite end-point comprised incident non-fatal CVD 
events (coronary revascularization, myocardial infarc-
tion, heart failure, cardiac arrest, cerebrovascular disease, 
and peripheral artery disease) and all-cause mortality. 
Follow-up was 99.9%, as one person was lost to follow-up 
because of incorrectly collected social security number.
Statistics
Statistical analyses were performed using SPSS (version 
20.0, Chicago, Illinois, USA), SAS (version 9.3, SAS Insti-
tute, Cary, North Carolina, USA) and R for Mac, ver-
sion 3.4.3 (R Project for Statistical Computing, Vienna 
University of Economics and Business Administration, 
Wien, Austria). Continuous traits were reported as 
mean ± standard deviation (SD) or as median and inter-
quartile range (IQR) when not normally distributed. 
Categorical data are shown as numbers (n) and percent-
ages (%). Continuous variables were compared using the 
pooled 2-sample t-tests or Mann–Whitney U tests as 
appropriate. Categorical variables were compared using 
Chi-square tests. EAT, PAT and CAT were analyzed both 
as continuous and as binary (split by the median fat level) 
variables. Cox proportional hazard regression models 
were performed to obtain hazard ratios (HRs) with 95% 
confidence intervals (CIs) for the risk of the compos-
ite end-point per mm increment of cardiac fat. Model 1 
was unadjusted. Model 2 was adjusted for age and sex. 
Model 3 was adjusted for CVD risk factors including age, 
sex, systolic blood pressure, LDL, BMI, smoking, dia-
betes duration and  HbA1c. Non-linearity was tested by 
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adding cardiac fat squared as a covariate to the models. 
The interaction of sex and cardiac fat on the risk of the 
composite end-point was analyzed in model 1–3. Pro-
pensity score matching of males and females was per-
formed to eliminate differences in confounding baseline 
characteristics (age, systolic blood pressure, LDL, BMI, 
smoking, diabetes duration and  HbA1c), and the resulting 
matched study population was analyzed for association 
of EAT and the composite end-point in males vs. females, 
respectively. The additive predictive value of EAT, PAT 
and CAT was tested with C-statistics and the net reclas-
sification index (NRI) [30]. A two-tailed p < 0.05 was con-
sidered statistically significant.
Results
Study population characteristics
Median follow-up time was 4.7 (IQR: 4.0; 5.3) years for 
the composite end-point of incident CVD and mortality. 
Of the entire population 248 (24%) experienced a com-
posite end-point. More men experienced the composite 
end-point compared to women [191 (28%) vs. 57 (16%), 
p < 0.001]. Women had higher LDL and higher total cho-
lesterol, and there was no sex-difference in other CVD 
risk factors assessed including age, smoking, diabetes 
duration and BMI (Table  1). Men had higher levels of 
CAT [12.1 (SD: 3.7) mm vs. 11.4 (3.5), p = 0.004] and PAT 
[7.1 (2.4) vs. 6.2 (2.6), p < 0.001] compared to women. 
EAT was not different in men vs. women [5.0 (1.8) vs. 5.0 
(1.9), p = 0.86] (Table 1).
Epicardial adipose tissue and cardiovascular disease 
and all‑cause mortality
EAT as a continuous variable was borderline associ-
ated with the composite end-point of incident CVD 
and mortality in the unadjusted model 1 [HR: 1.06 
(1.00; 1.14), p = 0.057], and the association was signifi-
cant in men [HR: 1.08 (1.01; 1.17), p = 0.033], but not 
in women [HR: 1.02 (0.89; 1.17), p = 0.76] (Additional 
file  1: Table  S1). The interaction of sex and EAT on 
the composite end-point was, however, not significant 
(p = 0.44). The association in men did not remain sig-
nificant in model 2 [HR: 1.05 (0.98; 1.13), p = 0.18] or 
after further adjustment (Additional file  1: Table  S1). 
EAT was not associated with the composite end-
point in a non-linear manner [HR: 1.00 (0.99; 1.00), 
p = 0.55]. In analyses where EAT was dichotomized 
by the median [4.6 (IQR: 3.8; 5.8)  mm], patients with 
high EAT levels (above the median) had an increased 
risk of the composite end-point in model 1 [HR: 1.46 
(1.13; 1.88), p = 0.004], and the association was signifi-
cant in men [HR: 1.54 (1.15; 2.10), p = 0.004], but not 
in women [HR: 1.22 (0.72; 2.06), p = 0.46] (Fig. 1). The 
association remained significant in the total population 
in model 2 [HR: 1.31 (1.01; 1.69), p = 0.038], and was 
borderline significant in model 3 [HR: 1.32 (0.99; 1.78), 
Table 1 Baseline characteristics
Data is expressed as means (SD), medians (IQR) and number (n) and percentage (%). Pooled 2-sample t-tests was used for parametric means (SD) or Mann–Whitney U 
tests for non-parametric data (median (IQR) values).  Chi2 test was used for categorical data
EAT epicardial adipose tissue, HbA1c glycated hemoglobin, HDL high-density lipoprotein, LDL low-density lipoprotein, PAT pericardial adipose tissue, CAT total cardiac 
adipose tissue
Characteristic Total Men Women p value
Participants, n (%) 1030 679 (66) 351 (34) < 0.001
Age, years 65 (10) 65 (10) 64 (11) 0.81
Current smoker, (%) 151 (15) 105 (16) 46 (13) 0.31
Diabetes duration, years 11 [6, 17] 12 [6, 17] 10 [5, 17] 0.19
Ischemic heart disease, n (%) 192 (19) 161 (24) 31 (8) < 0.001
Systolic blood pressure (mmHg) 136 (17) 134 (18) 138 (17) 0.001
Body Mass Index (kg/m2) 30.3 (5.7) 30.1 (5.1) 30.6 (6.6) 0.16
Cholesterol (mmol/l) 4.1 [3.5; 4.8] 4.0 [3.4; 4.6] 4.4 [3.8; 5.1] < 0.001
LDL (mmol/l) 2.0 [1.2; 1.8] 1.9 [1.5; 2.5] 2.1 [1.6; 2.8] 0.001
HDL (mmol/l) 1.2 [1.0; 1.4] 1.1 [0.9; 1.3] 1.3 [1.1; 1.6] < 0.001
Triglyceride (mmol/l) 1.8 [1.2; 2.5] 1.8 [1.2; 2.6] 1.6 [1.2; 2.3] 0.032
HbA1C (mmol/mol) 55 [48; 66] 55 [48; 65] 54 [46; 66] 0.69
P-creatinine (µmol/l) 79 [66; 98] 84 [73; 104] 67 [56; 83] < 0.001
CAT (mm) 11.9 (3.6) 12.1 (3.7) 11.4 (3.5) 0.004
EAT (mm) 5.0 (1.8) 5.0 (1.8) 5.0 (1.9) 0.86
PAT (mm) 6.9 (2.8) 7.1 (2.8) 6.4 (2.6) < 0.001
Composite end-point, n (%) 248 (24) 191 (28) 57 (16) < 0.001
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p = 0.057]. For male patients, high EAT levels remained 
significantly associated with an increased risk of inci-
dent CVD and mortality in model 3 [HR: 1.41 (1.01; 
1.96), p = 0.041] (Table  2). Using the propensity score 
matched study population (n = 534, 50% males/females) 
resulted in similar findings, where high EAT remained 
associated with an increased risk of incident CVD and 
mortality in the total population [HR: 1.54 (1.06; 2.23), 
p = 0.022] and a tendency was found in men [1.49 (0.94; 
2.36), p = 0.093] but not in women [1.44 (0.77; 2.68), 
p = 0.25]. No significant interaction was observed 
between high EAT levels and sex on the composite end-
point in model 3 (p = 0.50) or in the propensity score 
matched population (p = 0.95). 
While high EAT levels were associated with both 
mortality [1.61 (1.09; 2.38), p = 0.018] and incident 
CVD [1.41 (1.00; 1.97), p = 0.046] in the male popula-
tion in model 1, no significant association with either 
mortality [2.00 (0.84; 4.50), p = 0.09] or incident CVD 
[1.12 (0.58; 2.18), p = 0.74] was found for females 
(Additional file 2: Table S2).
a
b c
Fig. 1 Association of high vs. low EAT to risk of CVD and all-cause mortality. Kaplan–Meyer proportional hazards plot of epicardial adipose tissue 
(EAT) and risk of the composite end-point CVD or mortality in patients with EAT levels below the median (low EAT) group (blue) and above the 
median (high EAT) group (green). Hazard ratio (HR) 1.46 confidence interval (CI) 1.13; 1.88, p = 0.004 in the total population (a), HR 1.54 confidence 
interval (CI) 1.15; 2.10, p = 0.004 in men (b) and in women (c) HR: 1.22, CI 0.72; 2.06, p = 0.46
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Pericardial adipose tissue and cardiovascular disease 
and all‑cause mortality
PAT was not associated with the composite end-point 
in model 1–3, and, in contrast to EAT, sex did not mod-
ify the association (Additional file  1: Table  S1). PAT 
was not associated with the composite end-point in a 
non-linear manner [HR: 0.99 (0.98; 1.00), p = 0.31]. The 
median level of PAT was 6.3 (IQR: 4.8; 8.6) mm, and 
patients with high levels of PAT (above the median) 
did not have an increased risk of the composite end-
point in model 1–3 and sex did not modify the result 
(Table  3). No association was found of high PAT with 
either mortality or incident CVD in model 1–3 (Addi-
tional file 2: Table S2).
Total cardiac adipose tissue and cardiovascular disease 
and all cause‑mortality
CAT was associated with increased risk of the composite 
end-point of incident CVD and mortality in model 1 [HR: 
1.04 (1.00; 1.07), p = 0.035] but not when stratified into 
men and women (Additional file 1: Table S1). The asso-
ciation did not remain significant in model 2–3 or when 
the population was stratified by sex (Additional file  1: 
Table S1). CAT was not associated non-linearly with the 
composite end-point [HR: 1.00 (0.97; 1.01), p = 0.44]. 
Patients with CAT levels above the median [11.5 (IQR: 
9.2; 14.3) mm] did not have an increased risk of the com-
posite end-point in model 1–3 (Table 2). No association 
was found of high CAT with either mortality or incident 
CVD in model 1–3 (Additional file 2: Table S2).
Predictive value of cardiac adipose tissue in the risk 
assessment of cardiovascular disease and all‑cause 
mortality
When examining model performances using C-sta-
tistic we found similar results before and after adding 
EAT (both as a continuous and binary variable) in both 
unadjusted (model 1) and adjusted (model 3) analyses 
(Table  3). We found that in both model 1 and model 3, 
high EAT (above the median) and EAT (as a continuous 
variable) modestly improved predictive model perfor-
mance using net reclassification index (Table 3). Addition 
of EAT or high EAT to model 3 correctly reclassified a 
large proportion of the total population [19.6%, p = 0.035 
or 20.5%, p = 0.026, respectively] (Table 3). Additionally, 
in men the same trend was found although insignificantly 
(Table 3). In women, EAT or high EAT did not improve 
the net classification index.
Discussion
In this prospective study of 1030 patients with type 2 
diabetes, we found that high levels of epicardial adipose 
tissue levels (above the median) were associated with 
the composite end-point of incident CVD and mortal-
ity after 4.7  years of follow-up. There was, however, no 
evidence that epicardial adipose tissue, as a continuous 
variable, was associated with the composite end-point. 
When stratified by sex, the association of high epicar-
dial adipose tissue and risk of incident CVD and mortal-
ity remained for men, even after further adjustment for 
CVD risk factors (age, BMI, LDL, systolic blood pressure, 
Table 2 Association of high levels of cardiac fat (> median) with CVD and all-cause mortality
HR values are presented according to high (> median) vs. low (< median) levels of adipose tissue
Model 1 is unadjusted
Model 2 is adjusted for age, sex
Model 3 is adjusted for age, sex, LDL, diabetes duration,  HbA1c, systolic blood pressure, smoking and BMI
CI confidence interval, EAT epicardial adipose tissue, HR hazard ratio, PAT pericardial adipose tissue, CAT total cardiac adipose tissue
Adipose tissue Model Composite (n = 248) Men Women
Composite (n = 191) Composite (n = 57)
HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
High EAT 1 1.46 (1.13; 1.88) 0.004 1.54 (1.15; 2.10) 0.004 1.22 (0.72; 2.06) 0.46
2 1.31 (1.01; 1.69) 0.038 1.40 (1.05; 1.87) 0.024 1.08 (0.63; 1.83) 0.79
3 1.32 (0.99; 1.78) 0.057 1.41 (1.01; 1.96) 0.041 1.16 (0.62; 2.17) 0.65
High PAT 1 1.07 (0.83; 1.37) 0.62 0.95 (0.72; 1.27) 0.46 1.22 (0.72; 2.07) 0.46
2 0.90 (0.70; 1.16) 0.42 0.83 (0.63; 1.10) 0.21 1.15 (0.67; 1.95) 0.62
3 0.84 (0.63; 1.12) 0.23 0.79 (0.57; 1.09) 0.16 1.05 (0.56; 1.97) 0.87
High CAT 1 1.20 (0.93; 1.54) 0.16 1.14 (0.86; 1.52) 0.43 1.24 (0.73; 2.10) 0.43
2 1.02 (0.79; 1.31) 0.88 1.00 (0.75; 1.33) 0.99 1.10 (0.64; 1.87) 0.73
3 0.97 (0.72; 1.30) 0.82 0.97 (0.69; 1.35) 0.86 1.04 (0.55; 1.98) 0.62
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smoking, diabetes duration, and  HbA1c) indicating a 
potential novel sexual dimorphism of the pathogenic-
ity of EAT, which, however, needs confirmation in future 
studies. Epicardial adipose tissue (both as a continuous 
and binary variable) when added to the adjusted model 
(model 3) modestly improved predictive value in the 
assessment of risk of incident CVD and mortality and 
only when examined by net reclassification index.
Cardiac fat and prediction of CVD complications in patients 
with type 2 diabetes
In the search of novel biomarkers that could improve 
identification of patients with type 2 diabetes at risk of 
CVD, EAT as an imaging biomarker has gained atten-
tion due to its intimate location to the coronary vessels 
and the myocardium [2, 31]. A recent meta-analysis has 
provided evidence that EAT is associated with prevalent 
subclinical atherosclerosis, ischemia, and future major 
adverse cardiac events [32], but only a few longitudinal 
studies have evaluated the predictive potential of EAT as 
an imaging biomarker of future CVD. The Multi-Ethnic 
Study of Atherosclerosis (MESA) reported that CAT was 
associated with increased risk of coronary heart disease 
(CHD) in a community-based case–control study of 998 
controls and 147 cases that developed CHD over a 5 year 
period [4]. Cheng et  al. [5] confirmed these findings 
in patients with asymptomatic CHD, and furthermore 
found a trend that EAT could improve MACE prediction 
when added to the Framingham Risk Score and coronary 
calcium scoring (CCS). Following these findings, more 
longitudinal studies unanimously concluded that high 
levels of EAT were associated with increased risk of CVD 
in patients with known or suspected CHD [8–10, 14]. A 
recent study showed that EAT volume is higher and den-
sity lower in subjects with coronary calcium compared 
to subjects without, and that EAT was more significantly 
associated with MACE than the calcium score [33]. 
Despite the solid evidence of EAT and CVD in general, 
evidence from patients with type 2 diabetes is still sparse 
and the predictive potential of EAT in type 2 diabetes has 
not been determined. Our group has previously shown 
for high-risk patients with type 2 diabetes and albumi-
nuria that high-levels of cardiac fat were associated with 
increased risk of incident CVD or mortality in a 5-year 
follow-up study [12]. This study extends these findings to 
an unselected cohort of patients with type 2 diabetes.
The next step is to determine the clinical relevance, 
establish threshold values, and evaluate whether adding 
cardiac fat to existing cardiac risk algorithms improves 
prognostic performance. To this end a recent paper by 
Zhou et  al. demonstrated that prediction of obstruc-
tive CAD was improved when EAT > 100 ml (as a binary 
marker) was added to a model based on age, sex, angina, 
and calcium score in patients with stable angina [13]. In 
Table 3 Performance of adipose tissue in predicting the composite end-point
Adipose tissue variables are presented as continuous or as binary variables: high (> median) vs. low (< median) levels of adipose tissue
Model 1 is unadjusted
Model 3 is adjusted for age, sex, LDL, diabetes duration,  HbA1C, systolic blood pressure, smoking and BMI
CI confidence interval, EAT epicardial adipose tissue, HR hazard ratio, PAT pericardial adipose tissue, CAT total cardiac adipose tissue
All patients C‑statistics Net reclassification index
Model 1 (95% CI) Model 3 (95% CI) Model without vs. with adipose tissue
Percent (95% CI) p value
Model without adipose tissue 0.67 (0.63–0.72)
Model including
 EAT 0.53 (0.49–0.58) 0.68 (0.63–0.72) 19.6% (1.4–37.8) 0.035
 High EAT 0.54 (0.50–0.58) 0.67 (0.63–0.72) 20.8% (2.5–39.1) 0.026
Men
 Model without adipose tissue 0.65 (0.60–0.70)
 Model including
  EAT 0.54 (0.49–0.59) 0.66 (0.61–0.70) 17.7% (− 3.1 to 38.5) 0.09
  High EAT 0.55 (0.50–0.59) 0.65 (0.60–0.70) 19.6% (1.1–40.0) 0.06
Women
 Model without adipose tissue 0.66 (0.55–0.76)
 Model including
  EAT 0.50 (0.39–0.60) 0.66 (0.56–0.77) − 4.3% (− 42.8 to 34.1) 0.83
  High EAT 0.52 (0.43–0.60) 0.66 (0.55–0.77) 20.3% (20.6–61.2) 0.33
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the present study, we demonstrate for the first time in 
patients with type 2 diabetes a modest improvement in 
the prediction of incident CVD and mortality when EAT 
(both as a binary and continuous marker) was added to a 
model including age, sex, BMI, smoking, LDL cholesterol, 
and diabetes duration evaluated using net reclassifica-
tion index. Conversely, C-statistic is relatively insensitive 
at comparing models after inclusion of CVD risk fac-
tors [34], which may explain the lack of improvement in 
model performance when evaluated by this method.
Despite, EAT, PAT, and CAT have been independently 
associated with increased risk of CVD [4, 5, 10] their 
individual importance needs to be determined. In our 
study PAT was not associated with increased risk of inci-
dent CVD and mortality. Moreover, the physiological sta-
tus of EAT (e.g. inflamed vs. non-inflamed EAT) rather 
than EAT mass may be a superior measure of cardiac 
risk, as suggested by Oikonomou et al., who revealed in 
the CRISP-CT study that inflammation-induced changes 
in perivascular EAT assessed by fat attenuation on com-
puter tomography angiography (CTA) enhanced risk pre-
diction substantially above traditional risk factors [35]. 
Thus, more studies are warranted to determine the clini-
cal relevance of EAT, and to determine whether adding 
EAT mass or functional properties (e.g. inflammation) 
will be superior as cardiac risk measures.
Sex‑differences in adipose tissue distribution and CVD risk
Men have an android and visceral fat distribution com-
pared to women, and it is well known that both the 
amount but also the physiological properties (e.g. secre-
tion of inflammatory adipokines) of visceral fat are detri-
mental to cardiometabolic health [18–20]. Patients with 
visceral obesity and middle-aged subjects with suspected 
metabolic syndrome have higher levels of epicardial adi-
pose tissue thickness, which was moreover, associated 
with cardiac fibrosis development 1-year post-myocar-
dial infarction [36]. Therefore, the present finding that 
men have more CAT might offer a contributing explana-
tion as to why men are at a higher risk of CHD compared 
to women of similar age [15]. Curiously, in our study EAT 
levels were not different in men and women, but high 
EAT (> median) was only associated with increased risk 
of the composite end-point in men and not women. A 
recent study suggest this to be due to an increased patho-
genicity (e.g. increased inflammation) of EAT in men vs. 
women since EAT only in men was associated with sys-
temic inflammation represented by high-sensitive CRP 
levels, increased left ventricular mass, and subclinical 
myocardial dysfunction [37]. Another study supports a 
sexual dimorphism of the association of EAT and inflam-
matory markers (e.g. IL-6) as this was only found in 
male and not female rats [38]. Although the sex-specific 
association with hard CVD end-points, as shown in this 
study, is novel, it will need confirmation in larger trials, as 
we cannot exclude that the lack of association in women 
merely reflects the lower event rate in this population 
reducing overall power of the associations.
Clinical relevance of cardiac fat
The last decades of research in cardiac fat has shown 
EAT to be a promising novel imaging biomarker of car-
diovascular risk in patients with suspected or known 
CHD. Now important papers have emerged where EAT/
EAT attenuation measured by CTA improves the predic-
tive potential of existing cardiac risk models in patients at 
risk/with CHD [13, 35].
EAT is a transducer of the adverse effects of systemic 
inflammation and metabolic disorders on the heart, and 
thus, represents an important target for therapeutic 
interventions [39–41]. In patients with type 2 diabetes, 
there was recently reported a positive association of EAT 
and severity of coronary artery disease [42]. The present 
study extends this finding by demonstrating that EAT 
measured by echocardiography modestly improved risk 
prediction in patients with type 2 diabetes. Regarding 
pharmacological influences, EAT thickness at systole is a 
consistent independent predictor of new onset diabetes 
in patients with CAD treated with high-intensity statins 
[43]. Treatment with dapagliflozin or non-pharmaco-
logical exercise-based interventions might be means to 
improve systemic metabolic parameters and decrease the 
EAT volume in patients with/at risk of diabetes [44, 45].
Yet, more work is needed to fully establish the role of 
EAT in cardiac risk prediction and as a therapeutic target 
in asymptomatic patients with type 2 diabetes at with/at 
risk of CVD where CTA is not ruinously performed, and 
echocardiography is the initial option for EAT evaluation.
Limitations
Even though a strength of this study is its large scale 
where 1030 patients with type 2 diabetes were included, 
the study has some limitations. First, cardiac fat was 
measured by echocardiography and not by the gold-
standard magnetic resonance imaging or CTA limiting 
the conclusions of the study. However, cardiac fat thick-
ness measured by echocardiography has been shown to 
correlate with volumetric measurements [46]. Second, 
since we address sex differences in the predictive ability 
of cardiac fat, other sex-specific anthropometric meas-
ures of fat distribution (waist and hip circumference, 
android, gynoid, and visceral fat mass) would be highly 
relevant. Unfortunately, we did not have access to these 
measures, but we did account for BMI in our model 
allowing us to address the independent effect of cardiac 
fat without the contribution of overall adiposity. Third, 
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even though the population was large and allowed for 
subgroup analysis the event rate was smaller in the female 
population compared to the male population, which 
could reduce statistical power in the sex-divided sub-
group analysis thus limiting the conclusion. We did not 
find a significant interaction between sex and high EAT, 
which further limits the conclusion and suggests that the 
sex difference could be due to differences in sample size 
or baseline characteristics. To eliminate these differences 
between females and males the analysis was repeated in 
the propensity score matched study population. Results 
from this analysis indicated a sex difference in the associ-
ation of high EAT and the composite end-point, although 
replication of these findings are needed in future studies.
Conclusion
In this study in patients with type 2 diabetes, we found 
that high levels of epicardial adipose tissue (above the 
median) was associated with increased risk of the com-
posite end-point of incident CVD and mortality, particu-
larly in men, after 4.7  years of follow-up. High levels of 
EAT modestly improved predictive potential of cardiac 
risk when added to a model including available tradi-
tional CVD risk factors. Future studies are warranted to 
elucidate whether EAT has a role in the formal prognos-
tic clinical algorithms.
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